” Global Bispecific Antibody Market, Drug Sales and Clinical Pipeline Insight 2025″ Report Highlights:
-
Applications of Bispecific Antibodies
-
Global Bispecific Antibody Market Overview: Drug and Market Sales
-
Global Bispecific Antibody Market Opportunity: US$ 8 Billion by 2025
-
US and Japan Market Share Opportunity: andgt;40% by 2025
-
Bispecific Antibody Clinical Pipeline: 224 Drugs
-
Commercially Available Bispecific Antibody: 2 (HEMLIBRA and Blincyto)
Download Report Sample: https://www.kuickresearch.com/report-global-bispecific-antibody-market,-drug-sales–and-clinical-pipeline-insight-2025.php
The research and development of bispecific antibodies has emerged as a new unexplored growth frontier for pharmaceutical industry as per recent research study “Global Bispecific Antibody Market, Drug Sales and Clinical Pipeline Insight 2025″ published by Kuick Research. As per report findings, the market opportunity of bispecific antibodies is estimated to surpass US$ 8 Billion by 2025 driven by application of existing commercially available bispecific antibodies to other multiple indications and increasing regulatory approvals from developing and developed markets. Currently, there are 2 bispecific antibodies (HEMLIBRA and Blincyto) commercially available in the market with combined sales of less than US$ 1 Billion in 2018.
The market for bispecific antibodies is quiet bright as they are the new emerging trends in the market. BsAbs due their specificity are gaining a lot of interest from multiple stake holders from the pharmaceutical industry. Now with the improved technology, monoclonal antibody therapy witnessed a drastic transition and is becoming more acceptable due to its site specific approach. They have become a critical component of clinical treatment procedure for a variety of indications.
Therapeutic antibodies in various segments have made the transition from human conception to clinical reality over the past two decades and reached from labs to bedside of the patients. Now, many of mAbs are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. The market is no doubt flourishing and is sure to increase many folds as with due acceptance of clinicians and patients due to their targeted effect.
Currently, there are more than 200 bispecific antibodies in the clinical trials and this number is further expected to increase in coming years driven by research and development and the favorable commercial success to 2 bispecific antibodies available in the market. Most of bispecific antibodies are being developed for the treatment of multiple cancers followed by infectious disease, CNS disorders, inflammatory and autoimmune disorders. The future for the research and development of bispecific antibodies remains highly progressive and profitable option driven by the fact that increasing number of big and small pharmaceutical companies are allocating their resources and are collaborating with other stake holders of the industry.
1. History of Monoclonal Antibodies
2. Overview of Bispecific Monoclonal Antibody
3. Mechanism Of Action Of Bispecific Antibody
3.1 Trifunctional Antibody: Catumaxomab (Removabandreg;)
3.2 Blinatumomab
4. The Design and Engineering of IgG like Bispecific Antibodies
4.1 Quadroma (Hybrid Hydromas) Approach
4.2 “Knobs Into Holes” Approach
4.3 CrossMab Approach
4.4 Dual-Variable-Domain Immunoglobulin Approach
5. The Design and Engineering of Small Bispecific Antibodies
5.1 Bispecific Diabodies
5.2 Bispecific T-Cell Engager Antibodies (BiTEs)
6. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies
7. Applications of Bispecific Antibodies
7.1 BsMAb for Diagnosis of Infectious Diseases
7.1.1 Diagnosis of Bacterial Infections
7.1.2 Diagnosis of Viral Infections
7.2 BsMAb for Cancer Diagnostic
7.3 BsAbs Blocking Signaling Pathways
7.4 BsAbs Targeting Tumor Angiogenesis
7.5 Specific Delivery of Effector Compounds to Targets
7.6 Bispecific Antibodies and Gene Therapy
8. Global Bispecific Antibody Market Overview
8.1 Current Market Scenario
8.1.1 Catumaxomab (Removab)
8.1.2 Blinatumomab
8.1.3 Duligotumab
8.1.4 SAR 156597
8.2 Global Bispecific Antibodies Clinical Pipeline Overview
9. Global Bispecific Antibody Market Dynamics
9.1 Favorable Market Parameters
9.1.1 Target Patient Base
9.1.2 Severity Of The Disease
9.1.3 Unavailability Of Completely Curing Drugs
9.1.4 Side Effects of the Existing Drugs
9.1.5 Specificity of Monoclonal Antibodies in Targeting Cancer Cells
9.2 Commercialization Challenges
9.2.1 Stringent Regulatory Guidelines
9.2.2 Long Duration of Research and Development
9.2.3 Clinical Trial Timeline
9.2.4 High Cost for Research and Development
10. Global Bispecific Antibody Market Future Prospects
11. Global Bispecific Antibodies Clinical Pipeline by Company, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-I/II
11.5 Phase-II
11.6 Phase-III
12. Marketed Global Bispecific Antibodies Clinical Insight by Company and Indication
12.1 Emicizumab (HEMLIBRA)
12.2 Blinatumomab (Blincyto)
13. No Development Reported and Discontinued Global Bispecific Antibodies Clinical Pipeline by Company, Indication and Phase
13.1 No Development Reported
13.2 Discontinued
13.3 Market Withdrawal
14. Competitive Landscape
14.1 Ablynx
14.2 Adimab
14.3 Affimed Therapeutics
14.4 Amgen
14.5 AstraZeneca (MedImmune)
14.6 Chugai Pharmaceutical
14.7 Eli Lilly
14.8 EMD Serono
14.9 Emergent BioSolutions
14.10 Genentech
14.11 Genmab
14.12 Immunomedics
14.13 Jounce Therapeutics
14.14 MacroGenics
14.15 Merus
14.16 Neovii Biotech
14.17 NovImmune SA
14.18 OncoMed Pharmaceuticals
14.19 Pieris
14.20 Regeneron Pharmaceuticals
14.21 Roche
14.22 Sanofi
Figure 3-1: Mechanism of Action of Bispecific Monoclonal Antibody
Figure 3-2: Mechanism of Action of Catumaxomab
Figure 3-3: Mechanism of Action of Blinatumomab
Figure 4-1: Types of Approaches to Form IgG like Bispecific Antibodies
Figure 4-2: Method of Formation of Hybrid Hybridoma
Figure 4-3: Limitations of Hybrid Hybridoma
Figure 4-4: Steps involved in “Knobs into Holes” Approach
Figure 4-5: Three different CrossMabs are Obtained by Three Different Modifications
Figure 4-6: Method for formation of Dual-Variable-Domain Immunoglobulin
Figure 4-7: Advantages of Dual Variable Domain Immunoglobulin approach
Figure 5-1: Types of Bispecific Antibodies
Figure 6-1: Advantages of Bispecific Antibodies
Figure 7-1: Applications of Bispecific Antibodies
Figure 8-1: BLINCYTO – US v/s Rest of World Sales Share (%), 2017
Figure 8-2: BLINCYTO – US v/s Rest of World Sales Share (%), Q3’2018
Figure 8-3: BLINCYTO – US v/s Rest of World Sales (US$ Million), Q3’2018
Figure 8-4: BLINCYTO – Global Sales (US$ Million), Q1’2018 to Q3’2018
Figure 8-5: BLINCYTO – US and Rest of World Sales (US$ Million), Q1’2018 to Q3’2018
Figure 8-6: Global – Bispecific Antibodies Clinical Pipeline by Phase (%), 2019 till 2025
Figure 8-7: Global – Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2019 till 2025
Figure 8-8: Global – Inactive Bispecific Antibodies in Clinical Pipeline by Phase (%),2019 till 2025
Figure 8-9: Global – Inactive Bispecific Antibodies in Clinical Pipeline by Phase (Numbers), 2019 till 2025
Figure 9-1: Favorable Market Parameters Global Bispecific Antibody Market
Figure 9-2: Commercialization Challenges for Bispecific Antibody
Figure 10-1: Japan – HEMLIBRA Market Opportunity For Treatment of Hemophilia A ( US$ Million), 2019 – 2025
Figure 10-2: Global – HEMLIBRA Market Opportunity For Treatment of Hemophilia A- Inhibitors ( US$ Million), 2019 – 2025
Figure 10-3: USA – HEMLIBRA Market Opportunity For Treatment of Hemophilia A- Inhibitors ( US$ Million), 2019 – 2025
Figure 10-4: Global – HEMLIBRA Market Opportunity For Treatment of Hemophilia A – Non Inhibitors ( US$ Million), 2019 – 2025
Figure 10-5: USA – HEMLIBRA Market Opportunity For Treatment of Hemophilia A – Non Inhibitors ( US$ Million), 2019 – 2025
Figure 10-6: Global – Bispecific Antibody Market Opportunity ( US$ Billion), 2019 – 2025
Figure 14-1: Ablynx – Clinical Pipeline
Figure 14-2: Affimed Therapeutics – Clinical Pipeline
Figure 14-3: Amgen – Clinical Pipeline
Figure 14-4: EMD Serono – Clinical Pipeline
Figure 14-5: Emergent Bioscience – Clinical Pipeline
Figure 14-6: Genmab – Clinical Pipeline
Figure 14-7: Jounce Therapeutics – Clinical Pipeline
Figure 14-8: MacroGenics – Clinical Pipeline
Figure 14-9: Merus – Clinical Pipeline
Figure 14-10: Novimmune – Clinical Pipeline
Figure 14-11: OncoMed – Clinical Pipeline
Figure 14-12: Pieris Pharmaceuticals – Clinical Pipeline
Figure 14-13: Roche – Clinical Pipeline
